Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.
{iframe}http://thedailyrecord.com/2011/07/14/rockville-based-human-genome-sciences-inc-gets-approval-for-new-lupus-drug/{/iframe}